Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review / Jesus Rodriguez-Pascual, Antonio Cubillo
Background: Identification of clinical and molecular biomarkers to predict dynamic response or monitor in real-time the efficacy of antiangiogenic therapy represents a major point in the treatment of patients with advanced colorectal cancer. Several studies have been conduced to identify some predictive biomarkers to select patients who will benefit from bevacizumab, the most widely used antiangiogenic monoclonal antibody. Conclusion: After a decade since the introduction of bevacizumab, no effective predictive biomarkers are available in routine clinical practice. In this review, we summarized the potential candidate dynamic biomarkers that may play a role in this setting.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Current pharmacogenomics and personalized medicine - 15(2017), 2, Seite 81- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rodriguez-Pascual, Jesus [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (5 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL009084215 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL009084215 | ||
| 003 | DE-627 | ||
| 005 | 20231129104156.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220323s2017 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL009084215 | ||
| 035 | |a (KFL)prod_DARH_002AH.sgm.1D8B0B5FBF8D37FDF4642D512EA79FA170395CD0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Rodriguez-Pascual, Jesus |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review |c Jesus Rodriguez-Pascual, Antonio Cubillo |
| 264 | 1 | |c 2017 | |
| 300 | |a 1 Online-Ressource (5 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: Identification of clinical and molecular biomarkers to predict dynamic response or monitor in real-time the efficacy of antiangiogenic therapy represents a major point in the treatment of patients with advanced colorectal cancer. Several studies have been conduced to identify some predictive biomarkers to select patients who will benefit from bevacizumab, the most widely used antiangiogenic monoclonal antibody. Conclusion: After a decade since the introduction of bevacizumab, no effective predictive biomarkers are available in routine clinical practice. In this review, we summarized the potential candidate dynamic biomarkers that may play a role in this setting | ||
| 700 | 1 | |a Cubillo, Antonio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmacogenomics and personalized medicine |d Sharjah : Bentham, 2008 |g 15(2017), 2, Seite 81- |h Online-Ressource |w (DE-627)KFL000006556 |w (DE-600)2424232-9 |w (DE-576)30683636X |x 1875-6913 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2017 |g number:2 |g pages:81- |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1875-6921&volume=15&issue=2&spage=81 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 935 | |i IMPORT_0628_prod_DARH_01 | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2017 |e 2 |h 81- | ||